Exploring Biotricity, Inc. (BTCY) Investor Profile: Who’s Buying and Why?

You're looking at Biotricity, Inc. (BTCY) and wondering who is actually buying this stock as it navigates the remote patient monitoring space, right? The investor profile for this company is defintely not typical, which is the first sign you need to look closer. While institutional ownership sits at a remarkably low 1.86%, insider ownership is massive at nearly 39.37%, signaling a stark divide between the smart money on the sidelines and management who are heavily invested in their own Technology-as-a-Service (TaaS) model.

The question is, are the insiders buying because of the recent operational improvements, like the Q2 Fiscal Year 2026 revenue of $3.9 million-a 19% year-over-year jump-or are they simply trying to stabilize a stock that's still reporting a net loss, albeit a much improved one at $0.77 million? When you see a gross margin of 81.9% driven by recurring technology fees that make up 88.7% of revenue, you have to ask: is this a growth story the institutions are just missing, or is there a capital risk they see that the insiders are overlooking? Dive into the data to see exactly which funds are making the small bets, and why the retail crowd might be the most important factor in BTCY's near-term volatility.

Who Invests in Biotricity, Inc. (BTCY) and Why?

You're looking at Biotricity, Inc. (BTCY) and want to know who is buying the stock and what their thesis is. The quick takeaway is that the investor base is heavily skewed toward individual retail investors who are betting on the company's aggressive growth in the remote patient monitoring (RPM) space and its recent move toward profitability. Institutional money is present but still relatively small, which is typical for a micro-cap stock.

The core attraction is the company's financial trajectory in fiscal year 2025 (FY2025) and the clear path to scale. Biotricity, Inc. reported total revenue of $13.8 million for FY2025, a 14.3% year-over-year increase, with a strong gross margin of 76.6%. That kind of margin expansion is what gets growth investors excited. The company's inclusion on the Financial Times' list of The Americas' Fastest-Growing Companies 2025, with a growth rate of 256.4% over the analyzed period, also helps.

Key Investor Types: A Micro-Cap Mix

The investor profile for Biotricity, Inc. is a classic mix for a smaller, high-growth company in the medical technology (MedTech) sector, but with a clear dominance by one group. The company's listing on the OTCQB market means institutional ownership is naturally lower than a major exchange stock.

• Retail Investors: This is the largest, most active group. They are individual investors drawn to the high-growth narrative of remote patient monitoring and the potential for a large return if the company executes its plan and potentially uplists to a major exchange. They often buy into the mission, which you can read more about here: Biotricity, Inc. (BTCY): History, Ownership, Mission, How It Works & Makes Money.
• Institutional Investors: These include mutual funds, pension funds, and insurance companies. While the company has reported a low number of institutional owners (around 2 institutions holding approximately 48,263 shares), their presence signals a degree of professional validation. Their investment decisions are based on the company's improving financial health and market position.
• Hedge Funds: These funds may engage in short-term trading to profit from the stock's high volatility, or they might take a smaller, strategic position as a growth catalyst. The stock's daily volatility was high, moving 14.34% between its high and low on one recent trading day in November 2025.

Investment Motivations: Betting on Profitability and Scale

The motivation for buying Biotricity, Inc. stock boils down to a few concrete financial milestones and market trends. Investors are not here for dividends-the company is still in a growth phase and is not paying one.

The most compelling recent development is the company's move toward financial stability. Biotricity, Inc. achieved its first-ever positive Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $438,260 in the fourth quarter of FY2025 (Q4-FY25). This is a huge psychological and financial milestone for a growth company, signaling that the business model works and is scalable.

Here's the quick math on the subscription model: Biotricity, Inc.'s recurring Technology Fees grew 12% year-over-year to $12.6 million in FY2025, which represents over 10.5 times their Device Sales revenue. This subscription-based revenue stream is why institutional investors are starting to pay attention; it provides predictable, high-margin revenue.

The investment thesis rests on these key financial and operational improvements:

Investment Strategies: Growth at a Reasonable Price

Given the company's financials, the prevailing strategy is a mix of aggressive growth and a form of value investing, where investors see the stock as undervalued compared to its long-term potential in the RPM market. The stock price, at around $0.572 as of November 14, 2025, reflects a micro-cap valuation, but the growth numbers suggest a much larger potential.

• Long-Term Holding (Growth Investors): These investors are focused on the long-term vision of Biotricity, Inc. becoming a dominant player in the digital healthcare space. They are willing to overlook the net loss of $11.9 million in FY2025 because the gross margin is high and the company is achieving positive EBITDA. They defintely believe the company will achieve scalable profitability.
• Short-Term Trading (Hedge Funds/Active Retail): The stock's high volatility attracts traders looking to capitalize on price swings. The stock's price has been volatile over the past three months compared to the US market, making it a target for short-term plays.
• Value Investing (The Turnaround Play): Value investors are looking at the reduced net loss, which decreased by 20% year-over-year in FY2025, and the operational improvements as signs of an impending turnaround. They see the current market capitalization of around $14.4 million (as of August 2025) as a low entry point for a company with a trailing 12-month revenue of $14.5 million (as of June 2025).

The low institutional float means that any large purchase or sale can cause significant price movement, so the high volatility is a feature, not a bug, for active traders. Still, the long-term money is focused on the continued expansion of that high-margin recurring revenue base.

Next Step: Review the company's Q3-FY26 guidance to ensure the revenue and margin trends are holding up before making a capital allocation decision.

Institutional Ownership and Major Shareholders of Biotricity, Inc. (BTCY)

You're looking at Biotricity, Inc. (BTCY) and trying to figure out which big players are backing the company. The direct takeaway is that traditional institutional ownership is remarkably low, sitting at just 1.86% as of November 2025. [cite: 4 (from first search)] But, that low figure is defintely misleading because the real institutional money is in the form of beneficial ownership, primarily through convertible preferred stock.

For a small-cap company in the remote patient monitoring space, a low institutional float-the percentage of shares institutions hold-is common, but it also means the few large holders they do have wield disproportionate influence. Biotricity, Inc.'s total market capitalization is around $16.710 million, so every major move by a fund is a significant event. [cite: 4 (from second search)]

Top Institutional Investors: A Tale of Two Numbers

When you look at the standard 13F filings-the quarterly reports from investment managers-you see a tiny footprint. As of the latest data, Biotricity, Inc. has only 2 institutional owners who report holding a total of just 48,263 shares of common stock.

However, the real anchor money comes from a different class of shareholder. The most significant beneficial owner is Ionic Ventures, LLC, and its affiliated entities. They hold a massive position that includes both common stock and a large block of Series B Convertible Preferred Stock, which is essentially a future claim on common stock.

Here's the quick math on the largest known institutional and beneficial positions, which really tells the story of who's buying and why:

The position held by Ionic Ventures, LLC is more than 60 times the size of the entire reported 13F institutional ownership. That's the money that matters here.

Changes in Ownership: The Conversion Trend

The trend in ownership isn't about mutual funds quietly accumulating shares; it's about long-term, strategic investors converting their debt or preferred equity into common stock. This is a huge signal.

For example, earlier in 2024, 97% of the Preferred A shareholders converted their shares into Restricted Common Stock. This move shows strong, long-term commitment from existing shareholders who are locking in their investment, reducing immediate sell-off pressure, and betting on the company's future growth in the medical technology sector. They're not looking for a quick flip.

Key indicators of this strategic commitment:

• Conversion of preferred shares signals confidence in long-term equity value.
• The Ionic Ventures position is largely convertible, showing a belief in the stock's appreciation potential beyond a fixed dividend.
• The company's financial results for the six months ending September 30, 2025, showed a revenue increase to $7.76 million, up from $6.47 million in the prior year, which validates the growth thesis for these long-term holders. [cite: 9 (from first search)]

Impact of Institutional Investors: Strategy and Stability

In a micro-cap like Biotricity, Inc., the few large investors play a critical role that goes far beyond just holding shares. They are the company's stability. Their trading activity can cause significant price swings, but their long-term presence is what gives the company the runway to execute its strategy.

Because the institutional float is so low, management is often more directly accountable to these key beneficial owners like Ionic Ventures, LLC. Their influence is felt most in:

• Strategic Direction: Large beneficial owners can push for or support major strategic shifts, like the focus on recurring technology fees, which hit 88.7% of revenue in the quarter ending September 30, 2025. [cite: 8 (from first search)]
• Financial Stability: Their willingness to hold convertible preferred stock provides capital without the immediate dilution and market pressure of a common stock offering. This is vital for a company that reported a net loss of $1.36 million for the six months ending September 30, 2025, even while improving its operating profit. [cite: 9 (from first search)]
• Valuation Floor: Their deep research and large, long-term positions act as a soft valuation floor, signaling to the broader market that a significant investor has done the homework and believes the stock is worth holding.

Understanding this beneficial ownership structure is the key to understanding Biotricity, Inc.'s investor profile. If you want to dive deeper into how the company's core business model supports this long-term investment thesis, you can read more here: Biotricity, Inc. (BTCY): History, Ownership, Mission, How It Works & Makes Money.

Key Investors and Their Impact on Biotricity, Inc. (BTCY)

You're looking at Biotricity, Inc. (BTCY) and trying to figure out who's really driving the bus, and honestly, the answer is clear: it's the insiders and a few committed long-term holders. The company's investor profile is defintely not a typical BlackRock-heavy institutional story; it's a high-conviction, low-float play where management holds most of the cards.

As of the most recent data, institutional ownership sits at a remarkably low 1.86%. This means big mutual funds and ETFs aren't a major factor here. Contrast that with insider ownership, which is a massive 39.37%. When nearly two-fifths of the company is owned by the people running it-like Founder and CEO Dr. Waqaas Al-Siddiq-that tells you where the influence lies. Their interests are directly aligned with the company's long-term success, which is a powerful signal.

The Notable Shareholders and Their Stakes

While the institutional presence is small, a couple of names stand out. The largest reported institutional holder is Strengthening Families & Communities, LLC, though their total share count is a modest 48,263 shares. The more interesting player is Ionic Ventures, LLC, a major non-institutional shareholder whose recent moves highlight the financing structure of a growing Technology-as-a-Service (TaaS) company.

Here's a quick look at the shareholder landscape and the financial context that is attracting these investors:

• Insider Ownership: 39.37%-The primary source of control and decision-making.
• Institutional Ownership: 1.86%-Indicates low liquidity and high volatility risk.
• FY 2025 Revenue: $13.8 million-Up 14.3% year-over-year, showing solid TaaS growth.
• Q4 FY 2025 Milestone: First-ever positive Adjusted EBITDA of $438,260.

Recent Moves and Investor Influence

The influence on Biotricity, Inc. (BTCY)'s direction is overwhelmingly internal. When insiders own that much, they don't need to worry about activist investors forcing a strategic change. Their focus, as evidenced by the fiscal year 2025 results, is on execution: expanding gross margins to 76.6% and driving recurring Technology Fees, which hit $12.6 million for the year.

A recent and important move came from Ionic Ventures, LLC. As of a November 14, 2025 filing, they reported a beneficial ownership of 2,926,171 shares, representing 9.9% of the class. This stake includes shares issuable upon conversion of Series B Convertible Preferred Stock, which stems from a $1 million funding round in 2024.

What this tells you is that Ionic Ventures is a key financier and a long-term believer, but their Schedule 13G filing confirms they are a passive investor. They are not looking to change management or strategy; they are simply backing the existing plan. This financial commitment is a major vote of confidence in the company's shift toward profitability, which you can read more about in Biotricity, Inc. (BTCY): History, Ownership, Mission, How It Works & Makes Money.

Here's the quick math on why this matters: the high insider and committed long-term holder base provides stability, but the low institutional float means the stock price can be highly sensitive to trading volume or a single large order. You're trading on conviction, not on broad institutional consensus.

The table below summarizes the key investor types and their perceived impact on the company's trajectory:

The high insider ownership and the recent conversion of 97% of Preferred A shares into common stock by existing long-term shareholders in 2024 underscore a deep commitment to the company's future, particularly as it moves past a negative EBITDA of $3.2 million in FY2025 toward sustained profitability.

Market Impact and Investor Sentiment

If you're looking at Biotricity, Inc. (BTCY), the first thing you notice is a clear signal from the ownership structure: this is defintely a story driven by insiders, not the institutional behemoths I used to track at BlackRock.

The investor sentiment is best described as cautiously optimistic among those who know the business best, but largely indifferent or skeptical among the big funds. Insider ownership sits at a substantial range, reported as high as 39.37% of the float, or around 20.7% (5.53 million shares), which is a huge percentage for a publicly traded company. This tells you the people running the show-CEO Waqaas Al-Siddiq and other executives-have their interests tightly aligned with yours.

On the flip side, institutional ownership is remarkably low, hovering at just 1.86% or even as low as 0.03% (representing about 0.01 million shares). This low institutional float means the stock's price movements are more volatile and less buffered by the steady hand of pension funds or mutual funds.

• High insider ownership shows strong internal conviction.
• Low institutional float means higher volatility risk.

Who's Buying: Insiders vs. Institutions

The major shareholders are a mix of insiders and a handful of small institutional players. For example, one of the few institutional owners is Strengthening Families & Communities, LLC, holding a modest 48,263 shares. When you see this kind of profile, you're looking at a company where the retail investor (the individual investor) and the insiders are the primary drivers. The market capitalization, which was around $15.191 million as of November 14, 2025, reflects this micro-cap status, making it a high-risk, high-reward proposition.

Insider sentiment, based on recent trading activity, has been categorized as Neutral. This is not a strong 'Buy' signal, but it also doesn't show a panicked flight, which is a key stability indicator in a small company.

Recent Market Reactions to Financial Performance

The stock market has responded positively to Biotricity, Inc.'s demonstrable progress toward efficiency and scale, even with its small size. The most recent clear reaction came after the Q2 Fiscal Year 2026 earnings report (for the quarter ending September 30, 2025).

Following the announcement on November 14, 2025, the stock price saw a jump of 7.89%, closing at $0.53. Here's the quick math on why that happened: the company reported revenue of $3.9 million for the quarter, a 19% year-over-year rise, and a gross profit of $3.2 million. That pushed the gross profit margin up to an impressive 81.9%.

The real kicker for investors was the significant reduction in net loss to just $772,000, a major improvement from the $1.6 million loss in the prior year's period, and the achievement of a second consecutive quarter of positive EBITDA. This is exactly what growth investors want to see: revenue scaling faster than costs.

For the six months ending September 30, 2025, total revenue was $7.76 million, and the company posted a positive operating profit of $555,764, a huge turnaround from an operating loss in the prior year. This shows the Technology-as-a-Service (TaaS) model, where recurring technology fees made up 94% of Q3 FY2025 revenue, is starting to hit an economy of scale. You can dig deeper into these numbers by reading Breaking Down Biotricity, Inc. (BTCY) Financial Health: Key Insights for Investors.

Analyst Perspectives: The 'Hold' Consensus

Wall Street's official view on Biotricity, Inc. is a consensus 'Hold' rating, based on the limited coverage of only one or two analysts in late 2025. This 'Hold' rating, with a consensus score of 2.00 (on a 1 to 5 scale where 1.5 to 2.5 is Hold), means analysts advise maintaining your current position but not buying new shares or selling existing ones. It's the financial equivalent of a yellow light.

To be fair, the low analyst coverage is typical for a micro-cap stock with a market cap under $20 million. The major firms often don't initiate coverage until the company is larger and has a clearer path to sustained profitability. What this estimate hides, however, is the underlying tension: the company is showing strong operational metrics-like that 81.9% gross margin-but it still has a very small float and faces challenges like a predicted downside of -100.00% in some 12-month forecasts, which is a reflection of the inherent risk and volatility in a stock trading at under a dollar.

The analyst perspective is grounded in realism. They see the operational improvements driven by CEO Waqaas Al-Siddiq and the expansion of the remote patient monitoring (RPM) Technology-as-a-Service (TaaS) platform. But, they are also waiting for the company to fully cross the chasm to consistent, GAAP (Generally Accepted Accounting Principles) profitability and a more robust balance sheet before upgrading their rating. The next key action to watch for is the anticipated FDA filing for a new multi-parameter cardiac monitor by the end of Q1 next year, which could be the catalyst for an upgrade.